These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31597003)

  • 21. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune therapies in non-muscle invasive bladder cancer.
    Ho PL; Williams SB; Kamat AM
    Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Med Hypotheses; 2016 Jul; 92():57-8. PubMed ID: 27241256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
    Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
    Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
    Lammers RJ; Witjes JA
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?
    Tully KH; Cole AP; Krimphove MJ; Friedlander DF; Mossanen M; Herzog P; Noldus J; Sonpavde GP; Trinh QD
    Urology; 2021 Jan; 147():199-204. PubMed ID: 32805294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
    Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
    Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
    Hinotsu S; Akaza H; Naito S; Ozono S; Sumiyoshi Y; Noguchi S; Yamaguchi A; Nagamori S; Terai A; Nasu Y; Kume H; Tomita Y; Tanaka Y; Samma S; Uemura H; Koga H; Tsushima T
    BJU Int; 2011 Jul; 108(2):187-95. PubMed ID: 21176079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
    Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
    Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages.
    Khanna A; Yerram N; Zhu H; Kim S; Abouassaly R
    Urology; 2019 Feb; 124():120-126. PubMed ID: 30219556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational therapies for non-muscle invasive bladder cancer.
    Smaldone MC; Casella DP; Welchons DR; Gingrich JR
    Expert Opin Investig Drugs; 2010 Mar; 19(3):371-83. PubMed ID: 20078248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
    Lobo N; Bree KK; Hensley PJ; Nogueras-Gonzalez GM; Abraham P; Navai N; Dinney CP; Kamat AM
    BJU Int; 2022 Sep; 130(3):323-330. PubMed ID: 34847263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.